Arestat™ comprises two fundamentally different aspects of
our platform stabilization technology. Both utilize excipients
and buffers approved by the FDA and EMEA in an unconventional
manner to achieve the desired stability.
Both platform technologies are available for licensing for applications involving
therapeutic proteins, vaccines, medical devices and diagnostics.
If you would like to contact Arecor please use the form below.
Alternatively, please contact us at our Cambridge office:
|
Address: |
Arecor Limited, 2 Cambridge Science Park, Cambridge,
CB4 0FE, United Kingdom. |
|
Telephone: |
+44 1223 426 060 |
|
Fax: |
+44 1223 423 411 |
Enquiry Form